Rapport Therapeutics, Inc. Common Stock

RAPP · NASDAQ
Analyze with AI
9/30/2025
6/30/2025
3/31/2025
12/31/2024
Operating Activities
Net Income-$26,925-$26,732-$24,063-$19,980
Dep. & Amort.$256$252$244$260
Deferred Tax$0$0$0$0
Stock-Based Comp.$0$4,389$4,040$3,208
Change in WC$3,698-$3,370-$433$1,341
Other Non-Cash$5,506$391-$25$725
Operating Cash Flow-$17,465-$25,070-$20,237-$14,446
Investing Activities
PP&E Inv.-$134-$22-$291-$226
Net Acquisitions$0$0$0$0
Inv. Purchases-$101,620-$12,950-$43,671-$84,559
Inv. Sales/Matur.$44,978$35,476$64,557$116,715
Other Inv. Act.$0$92$436$0
Investing Cash Flow-$56,776$22,596$21,031$31,930
Financing Activities
Debt Repay.$0$0$0$0
Stock Issued$270,533-$63$6$0
Stock Repurch.$0$0-$1$0
Dividends Paid$0$0$0$0
Other Fin. Act.$0$0$0$7
Financing Cash Flow$270,533-$63$5$7
Forex Effect$0$0$0$0
Net Chg. in Cash$196,292-$2,537$799$17,491
Supplemental Information
Beg. Cash$55,172$57,709$56,910$39,419
End Cash$251,464$55,172$57,709$56,910
Free Cash Flow-$17,599-$25,092-$20,528-$14,672
Rapport Therapeutics, Inc. Common Stock (RAPP) Financial Statements & Key Stats | AlphaPilot